Alnylam Pharmaceuticals (ALNY) Q4 FY25 earnings call

Alnylam Pharmaceuticals concluded a transformational Q4 FY25, achieving GAAP profitability for the full year and exceeding its P5x25 goals, driven by the successful launch of AMVUTTRA for ATTR cardiomyopathy. The company is now focused on its Alnylam 2030 goals, aiming for global TTR leadership, sustainable innovation with blockbuster potential medicines, and scaling with discipline to achieve over 25% revenue CAGR and 30% non-GAAP operating margin by 2030. Despite anticipated Q1 2026 revenue phasing impacts, management remains confident in the long-term growth trajectory of its TTR franchise